Boston Scientific Invests €75 Million in Galway R&D Expansion, Cementing Ireland's MedTech Status
Medical device giant Boston Scientific has announced a €75 million investment in a major research and development expansion at its Galway facility, reinforcing Ireland's position as one of the world's leading hubs for cardiovascular innovation — and delivering a powerful signal of confidence in the country's life sciences sector at a time of global economic uncertainty.
The investment, supported by IDA Ireland and the Irish government, will fund the construction of new, purpose-built laboratories designed to develop and test next-generation medical technologies across a range of cardiovascular therapies. The announcement has been welcomed by government ministers, industry bodies, and local representatives as a landmark moment for Galway and for Ireland's MedTech sector.
Background
Boston Scientific has maintained a presence in Ireland for over 30 years, employing more than 7,000 people across sites in Galway, Cork, and Clonmel. The Galway facility is the company's primary European hub for cardiovascular device development, producing products including drug-coated devices, vascular balloons, and heart and oesophageal stents used to treat conditions such as heart disease, vascular disease, and stroke risk. The company's Irish operations are among the most significant in its global network, and the Galway site in particular has established a reputation for innovation and manufacturing excellence that has made it a cornerstone of the company's European strategy.
Ireland's MedTech sector is one of the largest and most dynamic in Europe, employing approximately 45,000 people directly and generating annual exports of over €13 billion. The country is home to nine of the world's top ten medical device companies, and the sector has been a major driver of economic growth and employment, particularly in the west of Ireland where Galway has emerged as a globally recognised hub for cardiovascular device development. The sector's success is built on a combination of factors including Ireland's highly educated workforce, its favourable tax environment, its membership of the European Union, and the strong relationships that have developed between industry, academia, and government over several decades.
Boston Scientific's investment in Galway builds on a €100 million investment the company made in its Galway campus in 2022, demonstrating a sustained and deepening commitment to Ireland as a centre for research, development, and manufacturing. The company's decision to invest further in Galway at a time of global economic uncertainty is a powerful endorsement of Ireland's competitive advantages as a location for high-value life sciences investment.
Key Developments
The new R&D laboratories will focus on developing technologies for heart failure and renal denervation — a procedure that disrupts nerve supply to the kidneys to help lower blood pressure, which affects an estimated 1.28 billion people worldwide. Lance Bates, executive vice president and president of Interventional Cardiology and Vascular Therapies at Boston Scientific, expressed confidence in the Galway team and the Irish government's support for future growth, describing the investment as a reflection of the "exceptional talent and innovation" that the Galway facility has demonstrated over many years.
Minister for Education and Youth Hildegarde Naughton welcomed the announcement, highlighting the importance of R&D and innovation to Ireland's economy and acknowledging Galway as an internationally recognised MedTech hub. The investment is expected to create new high-skilled jobs in research, engineering, and clinical science, and to further enhance the company's innovation capabilities on the west coast of Ireland. IDA Ireland, the state agency responsible for attracting foreign direct investment, described the announcement as a "significant vote of confidence" in Ireland's life sciences ecosystem.
Why It Matters
The announcement underscores the continued attractiveness of Ireland for foreign direct investment, particularly in high-value sectors like life sciences and medical devices. Ireland's MedTech sector is one of the largest in Europe, and investments of this scale help sustain the country's competitive advantage in attracting global companies at a time when many countries are competing aggressively for life sciences investment. The focus on cardiovascular innovation is particularly significant given the scale of the global burden of heart disease, which remains the leading cause of death worldwide. Technologies developed at the Galway facility have the potential to improve the lives of millions of patients around the world, making the investment not only economically significant but also of profound humanitarian importance. The investment also demonstrates the value of the long-term relationships that have been built between Boston Scientific and the Irish state, and the importance of consistent, supportive government policy in attracting and retaining major international investors.
Local Impact
For Galway and the west of Ireland, the Boston Scientific investment is a major boost to the regional economy and a further affirmation of the city's status as a world-class centre for medical device innovation. The creation of new high-skilled jobs in research and development will benefit not only the individuals employed but also the wider Galway economy, supporting local businesses, services, and communities. The investment is also expected to strengthen the links between Boston Scientific and the National University of Ireland Galway, which has developed a strong research partnership with the company over many years and which trains many of the engineers and scientists who work at the Galway facility. For Ireland as a whole, the announcement is a reminder of the importance of maintaining the conditions — including a skilled workforce, a supportive regulatory environment, and a competitive tax regime — that have made the country such an attractive destination for life sciences investment.
What's Next
Construction of the new laboratories is expected to begin in the coming months, with the facilities expected to be operational within two to three years. The expansion builds on a €100 million investment Boston Scientific made in its Galway campus in 2022, and is expected to be followed by further investments as the company continues to grow its Irish operations. Sources: RTÉ News, IDA Ireland, Boston Scientific Ireland
